Literature DB >> 16220222

Incidence and clinical correlation of anticentromere antibody in Thai patients.

Krisaree Pakunpanya1, Oravan Verasertniyom, Monchand Vanichapuntu, Prapaporn Pisitkun, Kitti Totemchokchyakarn, Kanokrat Nantiruj, Suchela Janwityanujit.   

Abstract

Anticentromere antibodies (ACA) are useful in assessing and classifying patients with mild variant of systemic sclerosis called calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias (CREST) syndrome. From their prognostic significance, we are interested in the prevalence and disease correlation in Thai patients. A total of 3,233 serum samples of patients with any musculoskeletal symptoms were sent for antinuclear antibody determination at Ramathibodi Immunology Laboratory Service between the years 1998 and 2001. Forty sera (1.23%) were ACA positive. These sera were from 27 patients with autoimmune diseases and 13 with nonautoimmune diseases. Among autoimmune group, scleroderma was the most common diagnosis (33.3%) with limited sclerosis being the most frequent variant. The percentages of autoimmune disease were almost the same among the low-titer (1:40) and the high-titer (1:640) groups. The study suggests that the prevalence of ACA in Thai patients is low. The presence of ACA detected in patients with vague musculoskeletal symptoms does not suggest a diagnosis of CREST syndrome. Even high-titer ACA can be found in nonautoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16220222     DOI: 10.1007/s10067-005-0005-4

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  18 in total

1.  Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis.

Authors:  D Vázquez-Abad; T Grodzicky; J L Senécal
Journal:  Clin Immunol       Date:  1999-02       Impact factor: 3.969

2.  Anticentromere antibody--clinical associations. A study of 44 patients.

Authors:  P Caramaschi; D Biasi; T Manzo; A Carletto; F Poli; L M Bambara
Journal:  Rheumatol Int       Date:  1995       Impact factor: 2.631

3.  Prevalence of scleroderma spectrum disorders in the general population of South Carolina.

Authors:  H R Maricq; M C Weinrich; J E Keil; E A Smith; F E Harper; A I Nussbaum; E C LeRoy; A R McGregor; F Diat; E J Rosal
Journal:  Arthritis Rheum       Date:  1989-08

4.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

5.  Patients with anticentromere antibodies, clinical features, diagnoses and evolution.

Authors:  P G Vlachoyiannopoulos; A A Drosos; A Wiik; H M Moutsopoulos
Journal:  Br J Rheumatol       Date:  1993-04

6.  Isolation and comparison of natural and recombinant human CENP-A autoantigen.

Authors:  A Martinez; D Sun; P B Billings; K M Swiderek; K F Sullivan; S O Hoch
Journal:  J Autoimmun       Date:  1998-12       Impact factor: 7.094

7.  Anticentromere antibody: an immunological marker of a subset of systemic sclerosis.

Authors:  T P Chorzelski; S Jablonska; E H Beutner; M Blaszczyk; M Jarzabek-Chorzelska; D Kencka; S Krasny; V Kumar; A Tchórzewska
Journal:  Br J Dermatol       Date:  1985-10       Impact factor: 9.302

8.  The CREST syndrome: a distinct serologic entity with anticentromere antibodies.

Authors:  M J Fritzler; T D Kinsella
Journal:  Am J Med       Date:  1980-10       Impact factor: 4.965

9.  Anticentromere antibodies (ACA): clinical distribution and disease specificity.

Authors:  H L Chan; Y S Lee; H S Hong; T T Kuo
Journal:  Clin Exp Dermatol       Date:  1994-07       Impact factor: 3.470

10.  Antibodies to centromere and centriole in scleroderma spectrum disorders.

Authors:  S Sato; M Fujimoto; H Ihn; K Takehara
Journal:  Dermatology       Date:  1994       Impact factor: 5.366

View more
  4 in total

1.  Letter to the editor. Re: Specificity of anti-centromere antibodies for scleroderma.

Authors:  P Roberts-Thomson
Journal:  Rheumatol Int       Date:  2007-06-13       Impact factor: 2.631

2.  New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays.

Authors:  Guang Song; Chaojun Hu; Heng Zhu; Li Wang; Fengchun Zhang; Yongzhe Li; Lin Wu
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

3.  Anticentromere antibody positive Sjögren's Syndrome: a retrospective descriptive analysis.

Authors:  Vasiliki-Kalliopi K Bournia; Konstantina D Diamanti; Panayiotis G Vlachoyiannopoulos; Haralampos M Moutsopoulos
Journal:  Arthritis Res Ther       Date:  2010-03-13       Impact factor: 5.156

4.  Anti-centromere antibody exhibits specific distribution levels among anti-nuclear antibodies and may characterize a distinct subset in rheumatoid arthritis.

Authors:  Nobuo Kuramoto; Koichiro Ohmura; Katsunori Ikari; Koichiro Yano; Moritoshi Furu; Noriyuki Yamakawa; Motomu Hashimoto; Hiromu Ito; Takao Fujii; Kosaku Murakami; Ran Nakashima; Yoshitaka Imura; Naoichiro Yukawa; Hajime Yoshifuji; Atsuo Taniguchi; Shigeki Momohara; Hisashi Yamanaka; Fumihiko Matsuda; Tsuneyo Mimori; Chikashi Terao
Journal:  Sci Rep       Date:  2017-07-31       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.